ALNYLAM PHARMACEUTICALS INC (ALNY)

US02043Q1076 - Common Stock

161.105  +2.44 (+1.54%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ALNYLAM PHARMACEUTICALS INC

NASDAQ:ALNY (2/27/2024, 9:44:44 AM)

161.105

+2.44 (+1.54%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap20.22B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ALNY Daily chart

Company Profile

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 2,002 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes five marketed products and over ten clinical programs, including several in late-stage development, across four strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.

Company Info

ALNYLAM PHARMACEUTICALS INC

675 W Kendall St

Cambridge MASSACHUSETTS 02142

P: 16175518200

CEO: John M. Maraganore

Employees: 2002

Website: https://www.alnylam.com/

ALNY News

News Image3 hours ago - Alnylam Pharmaceuticals, Inc.Alnylam to Webcast Presentations at Upcoming March Investor Conferences
News Image4 days ago - Investor's Business DailyWeight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

News Image12 days ago - Market News VideoNoteworthy Thursday Option Activity: CYH, SPHR, ALNY
News Image12 days ago - The Motley FoolWhy Alnylam Pharmaceuticals Stock Is Sinking Today

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

News Image12 days ago - Seeking AlphaAlnylam stock falls on Q4 topline miss (NASDAQ:ALNY)

Alnylam Pharmaceuticals (ALNY) reports lower-than-expected revenue for Q4 2023 and delays key Phase 3 readout due to changes in data analysis. Read more here.

News Image12 days ago - Seeking AlphaAlnylam Pharmaceuticals Non-GAAP EPS of -$0.77 in-line, revenue of $439.72M misses by $2.58M (NASDAQ:ALNY)

Alnylam Pharmaceuticals reports Q4 non-GAAP EPS in line with expectations, but misses revenue estimates by $2.58M.

ALNY Twits

Here you can normally see the latest stock twits on ALNY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example